Business Context and Reporting Period
This Form 8-K Current Report was filed by Aethlon Medical, Inc. (AEMD) on October 3, 2024. The filing reports significant changes in executive leadership effective as of the report date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Appointment of Permanent CEO: James B. Frakes was appointed as the permanent Chief Executive Officer, effective October 3, 2024. He previously served as Interim CEO since November 7, 2023, and will continue in his roles as Chief Financial Officer and Board member.
- Departure of COO: Guy F. Cipriani departed the Company as Chief Operating Officer, effective October 3, 2024. The filing states his departure was not related to financial results, operating results, or disagreements regarding reporting practices.
Guidance, Outlook, and Contingencies
The filing contains no financial guidance or outlook. Regarding contingencies, Mr. Cipriani is entitled to receive twelve months' severance and related separation benefits, subject to his execution and non-revocation of a waiver and release of claims agreement. The Company intends to enter into an amended executive employment agreement with Mr. Frakes to modify terms of his current agreement.
Investor Verification Checklist
- Verify the terms of the amended executive employment agreement for James B. Frakes in future filings.
- Confirm the execution of the waiver and release of claims agreement by Guy F. Cipriani to finalize severance obligations.
- Monitor subsequent filings for the appointment of a new Chief Operating Officer to replace Mr. Cipriani.